Exercise and Nutrition Education in Improving Physical Function and Quality of Life in Older Breast Cancer Survivors
Not Applicable
Terminated
- Conditions
- Anatomic Stage IIB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8ObesityPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03751449
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Castration Levels of TestosteroneStage IVB Prostate Cancer AJCC v8Metastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8Castration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma in the Soft TissueProstate Carcinoma Metastatic in the BonePSA ProgressionStage IVA Prostate Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT03751436
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Phase 2
Active, not recruiting
- Conditions
- Locally Advanced Digestive System Neuroendocrine CarcinomaLocally Advanced Pancreatic Neuroendocrine CarcinomaRefractory Pancreatic Neuroendocrine CarcinomaUnresectable Digestive System Neuroendocrine CarcinomaMetastatic Digestive System Neuroendocrine CarcinomaMetastatic Pancreatic Neuroendocrine CarcinomaRefractory Digestive System Neuroendocrine CarcinomaUnresectable Pancreatic Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT03736720
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Stony Brook Cancer Center, Stony Brook, New York, United States
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1
Withdrawn
- Conditions
- Stage III Primary Peritoneal Cancer AJCC v8Stage IIIA Primary Peritoneal Cancer AJCC v8Stage IIIB Fallopian Tube Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8Stage IVB Fallopian Tube Cancer AJCC v8Stage IVB Primary Peritoneal Cancer AJCC v8Stage II Fallopian Tube Cancer AJCC v8Stage II Ovarian Cancer AJCC v8Stage II Primary Peritoneal Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT03735589
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT03735095
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
Phase 1
Terminated
- Conditions
- Advanced Cutaneous Melanoma of the ExtremityAdvanced Sarcoma of the ExtremityPathologic Stage IIIB Cutaneous Melanoma AJCC v8Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Recurrent Cutaneous Melanoma of the ExtremityRecurrent Sarcoma of the ExtremityStage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT03727789
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT03727061
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1
Withdrawn
- Conditions
- Metastatic Prostate Carcinoma in the Soft TissuePSA ProgressionCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Prostate Carcinoma Metastatic in the BonePSA Level Greater Than or Equal to Two
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT03709550
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1
Active, not recruiting
- Conditions
- Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRefractory Ovarian CarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Primary Peritoneal CarcinomaRefractory Fallopian Tube Carcinoma
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT03691376
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Art in Improving Outcomes in Participants Undergo Surgery
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT03688945
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
© Copyright 2024. All Rights Reserved by MedPath